Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.
Rivas M, Pichel M, Colonna M, Casanello AL, Alconcher LF, Galavotti J, Principi I, Araujo SP, Ramírez FB, González G, Pianciola LA, Mazzeo M, Suarez Á, Oderiz S, Ghezzi LFR, Arrigo DJ, Paladini JH, Baroni MR, Pérez S, Tamborini A, Chinen I, Miliwebsky ES, Goldbaum F, Muñoz L, Spatz L, Sanguineti S; EPI-HUS Investigation Team; Members of the EPI-HUS Investigation Team. Rivas M, et al. Among authors: sanguineti s. Rev Argent Microbiol. 2023 Oct-Dec;55(4):345-354. doi: 10.1016/j.ram.2023.03.003. Epub 2023 Jun 8. Rev Argent Microbiol. 2023. PMID: 37301652 Free article.
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.
Zylberman V, Sanguineti S, Pontoriero AV, Higa SV, Cerutti ML, Morrone Seijo SM, Pardo R, Muñoz L, Acuña Intrieri ME, Alzogaray VA, Avaro MM, Benedetti E, Berguer PM, Bocanera L, Bukata L, Bustelo MS, Campos AM, Colonna M, Correa E, Cragnaz L, Dattero ME, Dellafiore M, Foscaldi S, González JV, Guerra LL, Klinke S, Labanda MS, Lauché C, López JC, Martínez AM, Otero LH, Peyric EH, Ponziani PF, Ramondino R, Rinaldi J, Rodríguez S, Russo JE, Russo ML, Saavedra SL, Seigelchifer M, Sosa S, Vilariño C, López Biscayart P, Corley E, Spatz L, Baumeister EG, Goldbaum FA. Zylberman V, et al. Among authors: sanguineti s. Medicina (B Aires). 2020;80 Suppl 3:1-6. Medicina (B Aires). 2020. PMID: 32658841 Free article. English.
RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.
Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF, Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P, Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Lloret SP, Millán S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F; INM005 Study Group. Lopardo G, et al. Among authors: sanguineti s. EClinicalMedicine. 2021 Apr;34:100843. doi: 10.1016/j.eclinm.2021.100843. Epub 2021 Apr 11. EClinicalMedicine. 2021. PMID: 33870149 Free PMC article.
Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.
Salinas F, Marelli BE, Sanguineti S, Goldbaum F, Muñoz L, Etchevers L, Silvestrini P, Notaro US, Salvetti NR, Zylberman V, Ortega HH. Salinas F, et al. Among authors: sanguineti s. Toxicol Appl Pharmacol. 2022 Jan 1;434:115796. doi: 10.1016/j.taap.2021.115796. Epub 2021 Nov 14. Toxicol Appl Pharmacol. 2022. PMID: 34785274 Free PMC article.
Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.
Farizano Salazar DH, Achinelli F, Colonna M, Pérez L, Giménez AA, Ojeda MA, Miranda Puente SN, Sánchez Negrette L, Cañete F, Martelotte Ibarra OI, Sanguineti S, Spatz L, Goldbaum FA, Massa C, Rivas M, Pichel M, Hiriart Y, Zylberman V, Gallego S, Konigheim B, Fernández F, Deprati M, Roubicek I, Giunta DH, Nannini E, Lopardo G, Belloso WH; EPIC Study Group. Farizano Salazar DH, et al. Among authors: sanguineti s. PLoS One. 2022 Sep 26;17(9):e0274796. doi: 10.1371/journal.pone.0274796. eCollection 2022. PLoS One. 2022. PMID: 36155545 Free PMC article.
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab')2 fragments in healthy volunteers.
Hiriart Y, Scibona P, Ferraris A, Belloso WH, Beruto V, Garcia Bournissen F, Zylberman V, Muñoz L, Goldbaum F, Spatz L, Colonna M, Sanguineti S, Simonovich VA. Hiriart Y, et al. Among authors: sanguineti s. Br J Clin Pharmacol. 2024 Apr;90(4):1142-1151. doi: 10.1111/bcp.15999. Epub 2024 Jan 30. Br J Clin Pharmacol. 2024. PMID: 38288879 Clinical Trial.
Specific recognition of a DNA immunogen by its elicited antibody.
Sanguineti S, Centeno Crowley JM, Lodeiro Merlo MF, Cerutti ML, Wilson IA, Goldbaum FA, Stanfield RL, de Prat-Gay G. Sanguineti S, et al. J Mol Biol. 2007 Jun 29;370(1):183-95. doi: 10.1016/j.jmb.2007.04.046. Epub 2007 Apr 24. J Mol Biol. 2007. PMID: 17512945
11 results